Ascletis Pharma (HKSE:01672) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01672 Ascletis Pharma Inc HKSE:01672
41 GF Score
Price HK$10.71
GF Value HK$0.14
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ascletis Pharma FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:01672
41GF Score
Ascletis Pharma Inc HKSE:01672
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ascletis Pharma (HKSE:01672) Overvalued in 2026?

Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued. The current stock price of HK$10.71 is trading 7550% above its estimated GF Value™ of HK$0.14. GuruFocus considers Ascletis Pharma to be Significantly Overvalued.

Key valuation signals for HKSE:01672:

  • FFO:
  • GF Value™: HK$0.14 vs. price of HK$10.71 (7550% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascletis Pharma Business Description

Other Exchanges ASCLF:USA2VJ:Germany
Address No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, HKG, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
41GF Score

Get the complete analysis for HKSE:01672

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$10.71
Price
HK$0.14
GF Value